# Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

> **NCT05814224** · NA · UNKNOWN · sponsor: **Centro di Riferimento Oncologico - Aviano** · enrollment: 164 (estimated)

## Conditions studied

- Hormone Receptor Positive Breast Carcinoma
- Breast Neoplasms
- Neoplasms, Breast
- Breast Diseases
- Antineoplastic Agents
- Aromatase Inhibitors
- ESR1 Gene Mutation

## Interventions

- **DIAGNOSTIC_TEST:** Liquid biopsy and CT scan

## Key facts

- **NCT ID:** NCT05814224
- **Lead sponsor:** Centro di Riferimento Oncologico - Aviano
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-22
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2023-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814224, "Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05814224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*